Ascendis Pharma

ASND NASDAQ
118.40
+3.51
+3.06%
Opening 15:24 07/22 EDT
Open
115.11
Prev Close
114.89
High
120.33
Low
113.84
Volume
300.64K
Avg Vol (3M)
324.53K
52 Week High
133.96
52 Week Low
53.21
% Turnover
0.64%
Market Cap
5.56B
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Ascendis Pharma ASND stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications. In addition to TransCon hGH, the Company has developed a pipeline of long-acting prodrug product candidates, such as TransCon Treprostinil for the treatment of pulmonary arterial hypertension (PAH), TransCon Peptides for the treatment of diabetes and TransCon Ranibizumab for the treatment of ophthalmology. It is also using its TransCon technology platform to develop TransCon Parathyroid Hormone (TransCon PTH) for hypoparathyroidism, a rare endocrine disorder of calcium and phosphate metabolism.
MORE >

Recently

Name
Price
%Change